Adam works with biotech companies to build and manage their patent portfolios, drafting patent applications and co-ordinating prosecution worldwide. He has particular experience advising clients in relation to strategy for protecting therapeutics (particularly immunotherapies, including adoptive cellular therapies), novel antibody technologies, diagnostics, and cellular agriculture inventions.
Adam leads our future food team which focuses on alternative protein technologies. He is a regular contributor to the wider conversation around protecting innovation in this exciting field.
Areas of Technical Expertise
- Molecular and Cellular Biology
- Infectious and Autoimmune disease
- Cell culture
- Stem cell technology
- Genetic engineering
Adam’s clients are based in Singapore, Europe and the US, and include biotech start-ups and SMEs, academic institutions, governmental organisations and multinational biotech corporations.
Adam has a first class degree in Biological Sciences from the University of Oxford, and a D.Phil. in Clinical Medicine from the University of Oxford.
He joined Mewburn Ellis LLP in 2012, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 2016, and became a Partner in 2020.
Adam has been listed as a "key lawyer" in the 2021 and 2023 editions of The Legal 500.